• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DOXORUBICIN Drug Record

  • Summary
  • Interactions
  • Claims
  • DOXORUBICIN chembl:CHEMBL53463 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    RUBEX
    VALRUBICIN IMPURITY, DOXORUBICIN
    NSC-123127
    ADRIAMYCIN
    DOXIL
    HYDROXYDAUNORUBICIN
    ADRIBLASTINA
    DOXORUBICIN
    (1S,3S)-3-GLYCOLOYL-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1,2,3,4,6,11-HEXAHYDROTETRACEN-1-YL 3-AMINO-2,3,6-TRIDEOXY-ALPHA-L-LYXO-HEXOPYRANOSIDE
    DOXORUBICIN HYDROCHLORIDE
    (8S-CIS)-10-((3-AMINO-2,3,6-TRIDEOXY-ALPHA-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-5,12-NAPHTHACENEDIONE
    ADRIAMYCIN®
    14-HYDROXYDAUNORUBICINE
    DOXIL®
    DOXORUBICINE
    14-HYDROXYDAUNOMYCIN
    DOXORUBICINUM
    drugbank:00997
    pubchem.compound:31703
    chemidplus:23214-92-8
    rxcui:3639
    chembl:CHEMBL53463

    Drug Info:

    Year of Approval 1974
    Drug Class antineoplastic agents
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    (6 More Sources)

    Publications:

    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Vikhanskaya et al., 1995, Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes., Int. J. Cancer
    Bosanquet et al., 2002, Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia., Leukemia
    Tassone et al., 2003, BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells., Br. J. Cancer
    Kobrinsky et al., 2005, Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue., Pediatr Blood Cancer
    Evdokimov NM et al., 2011, Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents., J Med Chem
    Tan S et al., 2015, Antiproliferative and apoptosis-inducing activities of novel naphthalimide-cyclam conjugates through dual topoisomerase (topo) I/II inhibition., Bioorg Med Chem
    Chhikara BS et al., 2012, Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate., J Med Chem
    Chen Z et al., 2010, A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis., J Med Chem
    Hayashi et al., 2006, Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction., Int. J. Mol. Med.
    Koehn et al., 2007, Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin., Anticancer Drugs
    Rody et al., 2007, Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response., Breast
    Azarova et al., 2007, Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies., Proc. Natl. Acad. Sci. U.S.A.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Menendez et al., 2006, DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes., Int. J. Mol. Med.
    Picaud et al., 2015, Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy., Cancer Res.
    Wojnowski L et al., 2005, NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity., Circulation
    Jabbour-Leung et al., 2016, Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer., Mol. Cancer Ther.
    Ohnstad et al., 2013, Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma., Cancer
    Xu et al., 2005, p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer., Clin. Cancer Res.
    Richter et al., 2015, WIP1 phosphatase as a potential therapeutic target in neuroblastoma., PLoS ONE
    Yang et al., 2011, p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer., Int. J. Oncol.
    Wong RP et al., 2007, p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3., Mol Cancer Ther
    Berns et al., 1998, Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer., Br. J. Cancer
    Jackson et al., 2012, p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer., Cancer Cell
    Davidovich P et al., 2015, Discovery of Novel Isatin-Based p53 Inducers., ACS Med Chem Lett
    Brachova P et al., 2013, The consequence of oncomorphic TP53 mutations in ovarian cancer., Int J Mol Sci
    Altés A et al., 2013, Pharmacogenetic analysis in the treatment of Hodgkin lymphoma., Leuk Lymphoma
    Cowin et al., 2012, LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin., Cancer Res.
    Kalra S et al., 2018, Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
    Bray J et al., 2010, Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide., Br J Cancer
    Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
    Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
    Thorn CF et al., 2011, Doxorubicin pathways: pharmacodynamics and adverse effects., Pharmacogenet Genomics
    Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res
    Bains OS et al., 2009, Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin., Drug Metab Dispos
    Gonzalez-Covarrubias V et al., 2009, Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors., Drug Metab Dispos
    Lal S et al., 2008, CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients., Cancer Sci
    Ai et al., 2008, The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer., Carcinogenesis
    Middlemas et al., 1999, Brain derived neurotrophic factor protects human neuroblastoma cells from DNA damaging agents., J. Neurooncol.
    Navrkalova V et al., 2013, ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin., Haematologica
    Yamaguchi et al., 2005, Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death., Oncol. Rep.
    Sagone AL Jr et al., 1979, The effect of BCNU and adriamycin on normal and G6PD deficient erythrocytes., Am J Hematol
    Allen JD et al., 2002, A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance., Cancer Res
    Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One
    Ujházy et al., 1994, Ecto-5'-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin., Int. J. Cancer
    Kurabayashi et al., 1994, Doxorubicin represses the function of the myogenic helix-loop-helix transcription factor MyoD. Involvement of Id gene induction., J. Biol. Chem.
    Lee et al., 2006, Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis., Biochim. Biophys. Acta
    Basho et al., 2017, Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab., JAMA Oncol
    Knuefermann et al., 2003, HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells., Oncogene
    Mavrakis et al., 2008, Tumorigenic activity and therapeutic inhibition of Rheb GTPase., Genes Dev.
    Reimer T et al., 2016, SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study., BMC Cancer
    Filipits et al., 2003, Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma., Clin. Cancer Res.
    Serie DJ et al., 2017, Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial., Pharmacogenet Genomics
    Megías-Vericat JE et al., 2018, Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy., Pharmacogenomics J
    Hertz DL et al., 2016, Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines., Pharmacogenomics
    Rossi D et al., 2009, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21., Leukemia
    Saadane et al., 1999, TAFII250, Egr-1, and D-type cyclin expression in mice and neonatal rat cardiomyocytes treated with doxorubicin., Am. J. Physiol.
    Aversano et al., 1983, Histochemical alterations of acute and chronic doxorubicin cardiotoxicity., J. Mol. Cell. Cardiol.
    Lebrecht et al., 2005, Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin., J. Pathol.
    De Mattia E et al., 2016, Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine., Pharmacogenomics
    Voon PJ et al., 2013, Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients., Br J Clin Pharmacol
    Bains OS et al., 2010, Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin., J Pharmacol Exp Ther
    Koschmann et al., 2016, ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma., Sci Transl Med
    Williams et al., 2007, Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions., BMC Mol. Biol.
    Shi W et al., 2011, Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans., Bioorg Med Chem
    Shchekotikhin AE et al., 2007, Naphthoindole-based analogues of tryptophan and tryptamine: synthesis and cytotoxic properties., Bioorg Med Chem
    Bolognese A et al., 2008, Antitumor agents 6. Synthesis, structure-activity relationships, and biological evaluation of spiro[imidazolidine-4,3'-thieno[2,3-g]quinoline]-tetraones and spiro[thieno[2,3-g]quinoline-3,5'-[1,2,4]triazinane]-tetraones with potent antiproliferative activity., J Med Chem
    Paciucci et al., 1991, Immunotherapy with IL2 by constant infusion and weekly doxorubicin., Am. J. Clin. Oncol.
    Peck et al., 2001, Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin., J. Clin. Oncol.
    Jordheim LP et al., 2015, Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma., Haematologica
    Lal S et al., 2008, Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients., Cancer Sci
    Gregers J et al., 2015, Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia., Pharmacogenomics J
    Maggini V et al., 2008, MDR1 diplotypes as prognostic markers in multiple myeloma., Pharmacogenet Genomics
    Sánchez-Tilló et al., 2014, The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma., Cell Death Differ.
    Wang et al., 2008, Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2., Carcinogenesis
    Abaza et al., Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells., Tumour Biol.
    Ohno et al., 2001, Expression of functional lung resistance--related protein predicts poor outcome in adult T-cell leukemia., Blood
    Sayed-Ahmed et al., 2001, Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy., Pharmacol. Toxicol.
    Niiya et al., 2004, Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells., Oncology
    Mourali et al., 2006, Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage., Mol. Cell. Biol.
    Lu et al., 2017, The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model., Cancer Lett.
    Hawinkels et al., 2016, Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors., Clin. Cancer Res.
    Malugin et al., HPMA copolymer-bound doxorubicin induces apoptosis in ovarian carcinoma cells by the disruption of mitochondrial function., Mol. Pharm.
    Lu et al., 2005, Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism., Mol. Pharmacol.
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Ciftci et al., 2003, Growth factors and chemotherapeutic modulation of breast cancer cells., J. Pharm. Pharmacol.
    Vinik et al., 2016, Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial., Target Oncol
    Wong TW et al., 2000, The decrease of mitochondrial NADH dehydrogenease and drug induced apoptosis in doxorubicin resistant A431 cells., Life Sci
    Vásquez-Vivar J et al., 1997, Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin., Biochemistry
    Yang et al., Effects of doxorubicin on pp60c-src kinase activity in polyoma virus MT antigen transformed cells., Anticancer Res.
    Jamieson D et al., 2011, Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy., Pharmacogenet Genomics
    Kurz et al., 2004, Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species., J. Biol. Chem.
    Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
    Reichwagen A et al., 2015, Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma., Pharmacogenomics
    Kozakai Y et al., 2014, Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line., Bioorg Med Chem Lett
    Faraji A et al., 2016, Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients., PLoS One
    Lal S et al., 2007, Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients., Pharmacogenomics
    Gelderblom H et al., 2014, Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study., Eur J Cancer
    Johnson et al., 2015, HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma., Oncotarget
    Bains OS et al., 2010, Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism., J Pharmacol Exp Ther
    Fan L et al., 2008, Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity., Pharmacogenet Genomics
    Harbottle A et al., 2001, Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance., Int J Cancer
    Low SK et al., 2009, Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients., J Hum Genet
    Jaboin et al., 2002, Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway., Cancer Res.
    Isaacs et al., 1997, Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin., J. Clin. Oncol.
    Schröterová et al., 2004, The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro., Physiol Res
  • DOXORUBICIN   NCF4

    Interaction Score: 2.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28763429 28485375 26799497 21048526 19448608 16330681


    Sources:
    PharmGKB

  • DOXORUBICIN   CYBA

    Interaction Score: 1.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28485375 25823784 21048526 19448608 16330681


    Sources:
    PharmGKB

  • DOXORUBICIN   PPM1D

    Interaction Score: 1.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25466181


    Sources:
    DTC

  • DOXORUBICIN   AKR1A1

    Interaction Score: 1.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21048526


    Sources:
    PharmGKB

  • DOXORUBICIN   SP3

    Interaction Score: 1.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17511886


    Sources:
    NCI

  • DOXORUBICIN   TAF1

    Interaction Score: 1.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10070062


    Sources:
    NCI

  • DOXORUBICIN   LRP1B

    Interaction Score: 1.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22896685


    Sources:
    CIViC

  • DOXORUBICIN   SLC22A16

    Interaction Score: 0.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28036387 20179710 17559346


    Sources:
    PharmGKB

  • DOXORUBICIN   SDHB

    Interaction Score: 0.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6672210 16278810


    Sources:
    NCI

  • DOXORUBICIN   SETD4

    Interaction Score: 0.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19204081


    Sources:
    PharmGKB

  • DOXORUBICIN   AKR7A2

    Interaction Score: 0.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20837989


    Sources:
    PharmGKB

  • DOXORUBICIN   RAC2

    Interaction Score: 0.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21048526


    Sources:
    PharmGKB

  • DOXORUBICIN   CBR1

    Interaction Score: 0.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21048526 19204081 19022938 19016765


    Sources:
    PharmGKB

  • DOXORUBICIN   CBR3

    Interaction Score: 0.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21048526 20007405 18551042


    Sources:
    PharmGKB

  • DOXORUBICIN   RPSA

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11493465


    Sources:
    NCI

  • DOXORUBICIN   MYB

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15001837


    Sources:
    NCI

  • DOXORUBICIN   ZEB1

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24013721


    Sources:
    CIViC

  • DOXORUBICIN   H2AX

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15489221


    Sources:
    NCI

  • DOXORUBICIN   GSTA1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 24215845 19448608


    Sources:
    PharmGKB

  • DOXORUBICIN   AKR1C3

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23116553 21048526 20837989


    Sources:
    PharmGKB

  • DOXORUBICIN   GADD45A

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7729953


    Sources:
    NCI

  • DOXORUBICIN   IL11

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9363868


    Sources:
    NCI

  • DOXORUBICIN   EZH2

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy ACY-957 + Doxorubicin
    Indication/Tumor Type diffuse large B-cell lymphoma
    Response Type sensitive

    PMIDs:
    25605023


    Sources:
    JAX-CKB

  • DOXORUBICIN   NOS3

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 25545243 21048526 19671875


    Sources:
    PharmGKB

  • DOXORUBICIN   ATRX

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

    PMIDs:
    26936505


    Sources:
    JAX-CKB

  • DOXORUBICIN   MYOD1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8119948


    Sources:
    NCI

  • DOXORUBICIN   BMP7

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • DOXORUBICIN   NQO2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 21946896


    Sources:
    PharmGKB

  • DOXORUBICIN   LINC00251

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • DOXORUBICIN   DOK5

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • DOXORUBICIN   TOP2A

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name AEZS-108, AN-152
    Novel drug target Established target
    Trial Name MTC-DOX, MTC-doxorubicin

    PMIDs:
    21388138 26211460 22276998 20170164 17016621 17351394 17010609 17578914 11752352 17089011


    Sources:
    DTC TdgClinicalTrial ClearityFoundationClinicalTrial TEND

  • DOXORUBICIN   ALDH3A1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOXORUBICIN   SLC28A3

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOXORUBICIN   EDN1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11589785


    Sources:
    NCI

  • DOXORUBICIN   CDKN1B

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12576455


    Sources:
    NCI

  • DOXORUBICIN   AFP

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15770640


    Sources:
    NCI

  • DOXORUBICIN   GATA3

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24141364


    Sources:
    PharmGKB

  • DOXORUBICIN   NQO1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10954045 9333325


    Sources:
    PharmGKB

  • DOXORUBICIN   NT5E

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7927909


    Sources:
    NCI

  • DOXORUBICIN   ABCC3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22016816


    Sources:
    DTC PharmGKB

  • DOXORUBICIN   FCGR3B

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1830717


    Sources:
    NCI

  • DOXORUBICIN   XRCC1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOXORUBICIN   CYP1A1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15588138


    Sources:
    NCI

  • DOXORUBICIN   NOS2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21048526


    Sources:
    PharmGKB

  • DOXORUBICIN   TOP2B

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21048526


    Sources:
    ClearityFoundationClinicalTrial PharmGKB TTD

  • DOXORUBICIN   TGM2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18174247


    Sources:
    NCI

  • DOXORUBICIN   GSTM1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23323945


    Sources:
    PharmGKB

  • DOXORUBICIN   ALK

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Dalantercept + Doxorubicin
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    16880530 28455243 26373572


    Sources:
    JAX-CKB NCI

  • DOXORUBICIN   FCGR3A

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1830717


    Sources:
    NCI

  • DOXORUBICIN   UGT1A6

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOXORUBICIN   ABCC4

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19696793


    Sources:
    PharmGKB

  • DOXORUBICIN   CYP2B6

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 20179710


    Sources:
    PharmGKB

  • DOXORUBICIN   RARG

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOXORUBICIN   ERCC1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOXORUBICIN   RUNX1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy I-CBP112 + Doxorubicin
    Indication/Tumor Type leukemia
    Response Type sensitive

    PMIDs:
    26552700


    Sources:
    JAX-CKB

  • DOXORUBICIN   ATM

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23585524


    Sources:
    CIViC PharmGKB

  • DOXORUBICIN   BIRC5

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16211302


    Sources:
    NCI

  • DOXORUBICIN   TGFB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12956904


    Sources:
    NCI

  • DOXORUBICIN   NOS1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21048526


    Sources:
    PharmGKB

  • DOXORUBICIN   NTRK2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12438277


    Sources:
    NCI

  • DOXORUBICIN   BCL2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16749867


    Sources:
    NCI

  • DOXORUBICIN   TOP1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21094049 17276690 19053767


    Sources:
    DTC

  • DOXORUBICIN   MAPK14

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16905201 15557793


    Sources:
    NCI

  • DOXORUBICIN   GSTP1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11351295


    Sources:
    PharmGKB

  • DOXORUBICIN   BAX

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12040435


    Sources:
    NCI

  • DOXORUBICIN   ABCC1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16330681


    Sources:
    PharmGKB

  • DOXORUBICIN   KMT2A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy I-CBP112 + Doxorubicin
    Indication/Tumor Type leukemia
    Response Type predicted – sensitive

    PMIDs:
    26552700


    Sources:
    JAX-CKB

  • DOXORUBICIN   SLCO1B1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27234217


    Sources:
    PharmGKB

  • DOXORUBICIN   PIK3CB

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16905201


    Sources:
    NCI

  • DOXORUBICIN   ABCC2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16330681


    Sources:
    PharmGKB

  • DOXORUBICIN   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11408511 29938344 22016816 25637052 18377430 25582575 18408561


    Sources:
    NCI PharmGKB

  • DOXORUBICIN   SRC

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7532928


    Sources:
    NCI

  • DOXORUBICIN   CYP1B1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOXORUBICIN   PIK3CA

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Doxorubicin + Temsirolimus
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type predicted – sensitive

    PMIDs:
    27893038 16905201 12761490


    Sources:
    JAX-CKB NCI

  • DOXORUBICIN   TP53

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Avastin + Doxorubicin + Docetaxel
    Indication/Tumor Type breast cancer
    Response Type sensitive

    PMIDs:
    26826118 23165797 16243804 25658463 21399868 17363498 9569050 22698404 26288684 24065105


    Sources:
    DTC JAX-CKB CIViC

  • DOXORUBICIN   ABCG2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11956086


    Sources:
    PharmGKB

  • DOXORUBICIN   BDNF

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10728907


    Sources:
    NCI

  • DOXORUBICIN   CYP19A1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DOXORUBICIN   G6PD

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    539595


    Sources:
    PharmGKB

  • DOXORUBICIN   AKT1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lymphoma
    Response Type decreased response
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    18708578


    Sources:
    JAX-CKB

  • DOXORUBICIN   PIK3CG

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16905201


    Sources:
    NCI

  • DOXORUBICIN   BRAF

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy PLX4720 + Doxorubicin
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    27924459


    Sources:
    JAX-CKB

  • DOXORUBICIN   BRCA1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12698198


    Sources:
    NCI

  • DOXORUBICIN   NR1I2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27561454


    Sources:
    PharmGKB

  • DOXORUBICIN   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300 29938344 20179710


    Sources:
    DTC PharmGKB

  • DOXORUBICIN   ERBB2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Guideline
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • DOXORUBICIN   APEX1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOXORUBICIN   ALDH1A1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344


    Sources:
    PharmGKB

  • DOXORUBICIN   CYP2C9

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DOXORUBICIN   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15465924 9187528


    Sources:
    NCI PharmGKB

  • DOXORUBICIN   POLK

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOXORUBICIN   CYP1A2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DOXORUBICIN   CYP2D6

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DOXORUBICIN   NFE2L2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18413364


    Sources:
    NCI

  • TEND: DOXORUBICIN

    • Version: 01-August-2011

    Alternate Names:
    DOXORUBICIN Primary Drug Name

    Drug Info:
    Drug Class antineoplastic agents
    Year of Approval 1974

    Publications:

  • TdgClinicalTrial: DOXORUBICIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: DOXORUBICIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL53463 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Kozakai Y et al., 2014, Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line., Bioorg Med Chem Lett
    Shi W et al., 2011, Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans., Bioorg Med Chem

  • NCI: DOXORUBICIN

    • Version: 14-September-2017

    Alternate Names:
    C456 NCI drug code

    Drug Info:

    Publications:
    Vikhanskaya et al., 1995, Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes., Int. J. Cancer
    Bosanquet et al., 2002, Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia., Leukemia
    Tassone et al., 2003, BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells., Br. J. Cancer

  • JAX-CKB: Doxorubicin

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Richter et al., 2015, WIP1 phosphatase as a potential therapeutic target in neuroblastoma., PLoS ONE
    Yang et al., 2011, p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer., Int. J. Oncol.
    Xu et al., 2005, p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer., Clin. Cancer Res.

  • PharmGKB: doxorubicin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Wojnowski L et al., 2005, NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity., Circulation
    Altés A et al., 2013, Pharmacogenetic analysis in the treatment of Hodgkin lymphoma., Leuk Lymphoma
    Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood

  • CIViC: DOXORUBICIN

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Jackson et al., 2012, p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer., Cancer Cell
    Wong RP et al., 2007, p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3., Mol Cancer Ther
    Berns et al., 1998, Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer., Br. J. Cancer

  • TTD: Doxorubicin

    • Version: 2020.06.01

    Alternate Names:
    D07VLY TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL53463

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: DOXORUBICIN

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21